Heterologous expression of equine CYP3A94 and investigation of a tunable system to regulate co-expressed NADPH P450 oxidoreductase levels.
Authors: Dettwiler Ramona, Schmitz Andrea L, Plattet Philippe, Zielinski Jana, Mevissen Meike
Journal: PloS one
Summary
# Editorial Summary: Heterologous Expression of Equine CYP3A94 and NADPH P450 Oxidoreductase Regulation Understanding the metabolic capacity of equine cytochrome P450 enzymes is crucial for predicting drug interactions and efficacy in horses, yet equine CYP3A94—the horse equivalent of the human CYP3A4 isoform responsible for metabolising roughly 50% of pharmaceutical drugs—remains poorly characterised. Dettwiler and colleagues expressed equine CYP3A94 and its obligate cofactor NADPH P450 oxidoreductase (POR) in mammalian V79 cells, using an innovative destabilising domain system intended to allow precise control of POR protein levels via a small-molecule "Shield-1" compound. The researchers demonstrated that CYP3A94 is indeed enzymatically active and that co-expression of POR significantly enhanced metabolic activity (measured using the fluorometric substrate BFC), increasing cytochrome c reduction substantially compared to CYP3A94 alone. Unexpectedly, Shield-1 treatment paradoxically *decreased* POR protein levels and reduced CYP3A94 activity by more than fourfold at physiologically relevant concentrations (500 nM–1 µM over 24 hours), suggesting an off-target effect that undermined the intended regulatory mechanism. Despite the regulatory system's shortcomings, the V79-CYP3A94/DD-POR cell line provides equine practitioners and researchers with a robust *in vitro* platform for investigating drug metabolism, protein–drug interactions, and potential species-specific differences in xenobiotic handling that could inform dosing protocols and predict adverse interactions in clinical practice.
Read the full abstract on PubMed
Practical Takeaways
- •This in vitro system provides a validated tool for characterizing equine drug-metabolizing enzyme activity, which may improve understanding of equine drug metabolism and potential drug interactions in clinical practice
- •The findings suggest that equine CYP3A94 function is dependent on adequate POR co-expression, similar to human systems, which has implications for how drugs are metabolized in horses
- •Further characterization of equine cytochrome P450 enzymes using this cell line could help optimize drug dosing and predict adverse drug interactions in equine patients
Key Findings
- •Equine CYP3A94 is metabolically active and its activity was significantly elevated (>4-fold increase) when co-expressed with POR
- •The DD-POR regulation system showed unexpected basal activity levels without Shield-1, indicating incomplete protein degradation
- •Shield-1 addition paradoxically decreased POR protein levels and CYP3A94 activity by more than 4-fold at concentrations of 500 nM and 1 µM